NL-OMON27781招募中不适用
A randomized phase III study for the treatment of recurrent epithelial ovarian cancer: chemotherapy alone versus chemotherapy followed by secondary cytoreductive surgery in patients with a disease-free interval of more than 6 months.
未提供0 个研究点目标入组 700 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 700
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Recurrence of epithelial ovarian cancer, after first line chemotherapy with a disease-free interval of at least 6 months, age> 18 years, WHO Performance status 0-2. The first-line therapy should have consisted of at least 4 courses of either cisplatin or carboplatin.
排除标准
- •More than one line chemotherapy, complete bowel obstruction, metastasized carcinoma (other tumor), leptomeningeal or brain metastases.
研究者
相似试验
已完成
不适用
TRIAL Relapsed AML 2001/01.Refractory or relapsed acute myeloid leukemia in children and adolescents.NL-OMON20351Dutch Childhood Oncology GroupDen HaagThe Netherlands400
尚未招募
不适用
A randomized phase III study in previously untreated patients with biological high-risk CLL: Fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumab.Chronic Lymphocytic LeukemiaNL-OMON25345Dr. C.H. GeislerRigshospitaletDept. of Hematology (L 4042)Blegdamsvej 9DK-2100 CopenhagenDenmarkTel: 0045 35451146Fax: 0045 35454283e-mail:geisler@rh.dk300
已完成
不适用
A randomized phase III study on the effect of the chimeric anti-CD20 monoclonal antibody (MabThera) during sequential chemotherapy followed by autologous stem cell transplantation in patients with relapsed or progressive B-cell non-Hodgkin’s lymphoma.on Hodgkin’s LymphomaNL-OMON29096Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl300
已完成
不适用
A randomized phase III study in previously untreated patients with biological high-risk CLL: fludarabine and cyclophosphamide (FC) versus FC and low-dose alemtuzumabCancerLeukaemiaISRCTN25180151Rigshospitalet (Denmark)300
进行中（未招募）
1 期
A randomized phase III study in previously untreated patients with biological high-risk CLL: Fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumabEUCTR2005-000309-75-CZHOVON CLL Group300